Memorial Sloan Kettering Cancer Center’s chief executive emailed all staff telling them they “need to do a better job” of disclosing industry relationships in the wake of a published report that the cancer center’s chief medical officer failed to disclose his extensive industry ties; the remedy to balance billing (the surprise bills patients receive after their insurance plan has paid the contracted amount with a provider) may lie at the federal or state level or possibly the courts; marijuana health research applications are stalled at the Drug Enforcement Administration, 2 years after it began taking the requests.
Memorial Sloan Kettering Cancer Center’s chief executive emailed all staff telling them they “need to do a better job” of disclosing industry relationships in the wake of a published report that the cancer center’s chief medical officer failed to disclose his extensive industry ties in dozens of research articles since 2013. The New York Times said the email referred to an article published over the weekend by the paper and ProPublica. The article found that José Baselga, MD, had received millions of dollars in consulting fees and ownership interests in healthcare companies, but he did not mention those ties in appearances at scientific conferences and in journal articles.
The remedy to balance billing (the surprise bills patients receive after their insurance plan has paid the contracted amount with a provider) may lie at the federal or state level or possibly the courts, Kaiser Health News reported. Kaiser examined one facet of the issue as it applies to self-funded plans under the federal Employee Retirement Income Security Act of 1974, or ERISA. ERISA does not prohibit balance billing, even as more states move to protect consumers against surprise medical bills.
Marijuana health research applications are stalled at the Drug Enforcement Administration, 2 years after it began taking the requests, The Wall Street Journal reported. The Department of Justice, led by Attorney General Jeff Sessions, a longtime critic of marijuana use, is not eager to process the applications, leading to bipartisan frustration. Researchers, including those working with veterans, want to study a wider variety of marijuana to know if it can be effective in alleviating pain, fighting seizures, combating depression, or relieving posttraumatic stress.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More